Abstract: Events of the past decade or so argue that there is little support in the literature for much of the specialty's treatment portfolio. The resulting call for 'evidence-based' treatment (not to mention the obvious intellectual bankruptcy of much of the clinical literature) has prompted many to argue that the randomized clinical trial (ACT) represents the future of orthodontic clinical investigation. The ACT, after all, is medicine's gold standard; what more is there to say? A popular, but ultimately divisive, corollary of this mimicry is the smug tendency to discount all other sources of data. In the face of a need for information, this attitude is also a wasteful conceit: in the end, the ACT can be applied only to a very narrow spectrum of orthodontic questions. Randomization implies equal susceptibility. Any prospective participant would have to be informed of this equality as part of the informed consent process. Unfortunately, it would be nearly impossible to enroll fully-informed subjects into any study whose alternatives are of markedly different morbidity: extraction versus non-extraction or orthodontics versus surgery. Thus, when measured against the most vexing clinical questions, the orthodontic ACT is almost by definition an amusing diversion -expensive, but relatively trivial in scope. Uke it or not, it seems reasonable to conclude that most of the specialty's comparative clinical data will have to be generated by way of non-randomized designs In which care Is taken to minimize the various known sources of bias. There probably is no other way.
The present communication is an after-the-fact addition to Prospective Clinical Research in Orthodontics, a meet· ing designed to showcase yet another round of progress reports from 'the first controlled studies' in orthodontics. Given that the quasi-experimental Saint Louis University/ University of Michigan Class II treatment comparisons are productive, albeit philosophically discrepant charter members of this pioneering cohort, their lowly estate is significant and worthy of extended comment.
Like children playing at being adults, many in orthodontics feel that the road to scientific maturity lies in imitating medicine, no matter what the cost and regardless of outcome. There is a tendency, therefore, to see the means of investigation as an end in itself and, by exten· sion, to discount all other sources of data. For example, it is a common strategy to show slides depicting some sort of scala naturae in which clinical research designs ascend from the slime of retrospection to the perfection of the randomized clinical trial (RCT). At a time when the specialty is under attack from a variety of barbarian hordes and its main defenses are timely, adequately designed clinical studies, the . blanket assertion that truly meaningful data can come only from an RCT is self-serving and inappropriate; it is the equivalent of saying, 'let them eat cake'. A few dyspeptic comments are in order.
History teaches that orthodontists tend to be professionally successful, regardless of their educational back· ground or choice of appliances; few look to 'science' as a source of practical clinical guidance. Perhaps as a result, disagreement was, until recently, largely recreational and for the most part limited to superficial tactical details, such as type of appliance (edgewise, bioprogressive, headgear, bionator, etc.) , slot size and angulation, interbracket distance, and the like. It was harmless sport because, at the same time, there was general agreement concerning the basic strategies of treatment. Extraction, for example, was seen as an answer to crowding and protrusion; surgery, as an answer to severe skeletal discrepancies. Times have changed. For a variety of reasonsspecialist/generalist turf wars, fear of litigation, busyness problems -entire treatment strategies have come under attack, both from within and without the specialty. These attacks have taken their toll.
Some of our critics, for example, argue that bicuspids should never be extracted or that surgery is tantamount to malpractice. The bitterness of the disagreement and the fervor of the participants is a threat to the public health; it threatens the well being of the specialty; it distorts clinical judgement. A major problem with the various revisionist arguments is that they call for alternatives that have never. be.en shown to be as orthodontically effective as the treatments they would replace. For example, one would have to achieve 12 mm of stable expansion to equal the 5 mm of space per quadrant created routinely by bicuspid extraction (the width of .a bicuspid minus the ancho~age lost during space closure). Wishful thinking aside, the literature argues that contemporary 'arch-devel-J • opment' methods fall far short of this requirement, as do fanciful functional-appliance substitutes for surgery ('bite forward ... forever'). Accordingly, it is important that we examine carefully the arguments against extraction and surgery, because, if they are true, it would mean that we have no safe, effective treatment for a large segment of the orthodontic population. Unfortunately, in contrast to superficial technical details, many of our basic orthodontic strategies are surprisingly difficult to study in real time. Given a desire to compare, say, arch leveling with 0.018-inch and 0.022-inch slots or early treatment with headgear and bionator, a careful 'retrospective' comparison probably will provide data that are 'good enough', both because it is easy to obtain samples that were similar before treatment and because the contrasts themselves are only of mild-to-moderate importance. In contrast, if one wants to document .the supposed superiority of say, nonextraction edgewise orthodontic treatment {better function, more pleasing profiles, greater stability, etc.), one cannot simply round up a few ex-patients and compare outcomes. Comparisons between groups formed on the basis of a clinician's treatment assignment tend to be compromised by 'susceptibility bias', a systematic segregation driven by the simple fact that many types of malocclusion seem uniquely susceptible to a specific treatment. For example, if extraction and non-extraction patients were systematically different before treatment (crowded Cion Onh Rn I. 1998,'88-9) J 89 and protrusive versus spaced and 'flat'), differences after treatment would defy interpretation. To effect a meaning· ful comparison, therefore, outcomes must be compared in patients who initially were similar and thus equally susceptible to both treatments.
Clearly, a well-designed randomized clinical trial would serve to eliminate susceptibility bias, along with a variety of other biases, both known and unknown. A key prereq· uisite to the conduct of a clinical trial is that there be true uncertainty about the relative efficacy of the various arms of the trial ('equipoise'; (2)). Individual orthodontists, however, commonly do not share the uncertainty of the refereed literature. As a result, they might not agree with, and thus would be unable to render, a treatment dictated by random assignment. Baumrind's method of 'clinician· preferred' treatment assignment (3) seems to address these requirements and problems by providing an empirical definition of uncertainty and by ensuring that treatment is prosecuted by a clinician who happens to agree with the randomization. It is my opinion, however, that this ingenious approach does not solve the problem of informed consent.
Because great pains must be taken to determine and document equal susceptibility to all treatments, a partici· pant in a randomized clinical trial is usually subjected to a more thorough analysis than is the average orthodontic patient. From the standpoint of hypothesis testing, there· fore, it is probable that the RCT would serve to eliminate bias and to equalize experimental conditions. From the standpoint of a prospective subject, however, randomiza· tion can never equalize the anticipated pain, discomfort, and inconvenience of the various arms of the trial. Unfor· tunately, many of the most pressing questions in or· thodontics -those asked in the clinic and. in court, rather than those offered up for ritual slaughter at meetings and in monographs -involve treatments that differ greatly in terms of anticipated pain, discomfort, and inconvenience. Thus, if all things (except the treatments to be compared) really are equal and the patient knows that they are equal, how can a sample ever be recruited?
What sort of subjects, for example, would agree to surgery if they understood -i.e. were fully-informedthat they could be treated equally well orthodontically? ('Mrs. Jones, your daughter can be treated orthodontically or surgically; however, we flipped a coin and it came up surgery. Sign here.') Some no doubt would agree to partie· ipate, perhaps in the hope that they will be randomized to the less morbid arm of the trial. If they are lucky, fine; if 90 I Clin Orrh R<J I. 111911.88· 91 not, they can always withdraw. Unfortunately, even if a few surgery patients or a few extraction patients happen to make it this far, there is one last hurdle: would fully-informed subjects permit themselves to be randomized to a surgery or extraction arm if pains were taken to elicit a preference? As noted by Kodish et al. (4) , 'the autonomy principle dictates that patients' personal values and motivations ~e given the highest priority in reaching a treatment decision.' I would argue, therefore, that many (but surely not all) non-trivial orthodontic trials can succeed only to the extent that a prospective subject's right to informed consent is abridged. Many disagree with this judgement, especially those who seek to bring the enlightenment of randomized trials to those toiling in the darkness of retrospective investigation.
Elsewhere in this issue, Baumrind has noted that he is 'not greatly concerned' by my ethical reservations. As I understand it, he feels that empirical uncertainty (i.e. among-clinician disagreement) is not the same thing as equal susceptibility. Even in the face of uncertainty (as defined by evenly divided opinion), one treatment will probably turn out to be better than the other. Based on this fine distinction between uncertainty and equal effect, it is argued that it would be misleading/unnecessary to tell prospective subjects that they probably would be served equally well by either arm of the trial. I doubt that this argument can be sustained.
In tennis, if you cannot see the ball out, you have to call it in. In the clinic, however, if opinion is so evenly divided that one treatment option is about as popular as the other, I would argue that the two must be assumed, at least provisionally, to be equally effective. If it is assumed that the two treatments are equal, then this information must be shared with prospective subjects. Indeed, in Baumrind's approach, among-clinician disagreement is the main eligibility requirement. If eligible subjects also must be equally susceptible, then from the standpoint both of the study and its participants, disagreement also defines equal susceptibility. QED. More to the point, if prospective subjects were informed of the among-clinician disagreement that defined their eligibility and were pressed for a preference, how many would allow themselves to be assigned the more morbid option?
It should come as no great surprise, therefore,. that the only trials that have managed to honor the details of their original application are those designed to compare technical details, not basic strategies. Although a mean-spirited observer might question the need for 10 years of support for each of three studies of 'headgear versus function· als', others apparently feel that the mere existence of these trials signals a scientific coming-of-age for or· thodontic clinical research. Unfortunately, in its or· thodontic incarnations, the RCT is a somewhat debased gold standard.
In the Wi~ard of 0~. Professor Marvel asked the four awed supplicants to 'pay no attention to that man be· hind the curtain'. In the world of the orthodontic ran· domized clinical trial (surely the metaphorical equivalent of the Emerald City), we are asked by other professors to be equally awed and equally selective in our atten· tion. For example, we are asked (or at least expected) to ignore the lack of blinding during and after treatment, not to mention the probable impact of the so-called 'Hawthorne effect'. The. goodness of a treatment out· come depends on the orthodontist's efforts and the pa· tient's cooperation, both of which might well be elevated to supra-normal levels by dint of both parties' known participation in a clinical trial. Moreover, be· cause of the time and money invested in each of a relatively small coterie of subjects, orthodontic RCTs sometimes feature vigorous, but scientifically question· able, steps to achieve exalted levels of patient compli· ance (e.g. periodic telephone calls to restore flagging enthusiasm and cooperation). Indeed, even the act of taking the occasional peek at the preliminary data ('the headgear patients are doing fine, but the functionals are lagging behind ... '), presumably for the purpose of issuing breathless communiques and news flashes at various meetings throughout the world, is seen by some as a violation of the RCT ground rules. Moreover, as al· luded to elsewhere in this volume, there are a number of practical problems that may prove equally damaging to the successful completion of a non-trivial orthodontic RCT.
Orthodontic treatments take years to finish and even longer to evaluate. Thus, a truly useful RCT would have a time frame (15-20 years) approaching that of a major medical trial (and exceeding the residual professional life of most of the current principal investiga· tors). Indeed, an orthodontic trial also would probably outlive its working hypothesis. Most damaging, how· ever, is the certainty of sample attrition and the atten· dant loss of statistical power. If you start with 300, a one-in-ten response is adequate; if you start with 30, you end up with an exceptionally expensive case report. Ultimately, orthodontic investigators will have to assess johnston. The stru~~~tle in clinical investi~ation their goals and priorities. The quest for man-powered flight was ennobling, expensive, and the subject of sev· eral fascinating Public Broadcasting specials; however, it did little for the person faced with, say, the rigors of a coach/class flight from Detroit to Dallas. Is it to be form or substance? As noted by Feinstein (5) In the end, if 'many ·of the desirable scientific features associated Jwith randomized clintcal trials' can be achieved without randomization, then there is no need to limit one's perspectives to narrow, trivial problems merely because they lend themselves easily to the Rcr genre. The tail need not wag the dog.
Based on the reasoning outlined in this brief commu· nication, the Saint Louis University/University of Mich· igan response to the NIDR request for applications opted for the substance and promise of a partially retrospective design over the form and pretence of a ran· domized clinical trial. Our implementation of Feinstein's call for 'suitable planning' took the form of a statistical algorithm designed to identify samples of patients who, at the start of treatment, were similar with ·'respect to the features that normally dictate the choice of treat• ment strategies (crowding, protrusion, overjet, and the like). Given this approach, we were able to go well beyond the narrow scope of a prospective trial to exam· ine treatment alternatives that could never be random· ized to fully-informed subjects (e.g. extraction versus non-extraction; orthodontics versus surgery). The results of these studies will be examined elsewhere in this issue. In the meantime, I would argue that, for orthodon· tics, 'the first controlled studies' are much like teaching a dog to play the piano -an interesting achievement, but hardly a benchmark against which all other musical activities must be judged. 
Resumen
Eventos en esta ultima Jecada demuestran que hay poco apoyo en Ia literatura con respecto a todo lo que incluye Ia carpeta de tratamientos de Ia especialidad. La reclamacion del tratamiento basado en Ia evidenda (por mencionar Ia falta de material intelec· tual dn Ia literatura cllnica) ha impulsado a muchos a argumentar que Ia investigation clinica aleatorizada (ICA) represents el futuro de Ia investigation cllnica en Ia ortodontica. La ICA es, despues de todo Ia norma.en investigaciones medicas. Una tendencia popular, pero dh·isiva. es Ia consequencia de estra mimica a descontar todas las otras fuentes de datos. Ante Ia necesidad urgente de informa· cion, esta actitud es una vanidad malgastadora: a un extrema, Ia ICA solo se puede aplicar a un espectro muy limitado en las pre· guntas hechas en investigaciones de ortodoncia. Aleatori:ado (al a:ar) implica igualdaJ de suseptibilidad. Cualquier participantc: prospecto tiene que ser informado de esta igualdad como pane del proceso de consentimiento informado. Desafortunadamente, es casi imposible obtener participantes totalmente informados en cualquier investigacion que conlleve alternativas notablemente diferentes: extraccion contra no-extraer o cirugia contra ortodoncia. Asi que, cuando se compara con las preguntas clinicas mis exigentes, el uso de ortodoncia de Ia ICA es casi por definicion una proposici6n costosa, pero relath·emente trivial en alcan:e. Nos guste o n6, parece razonable concluir que Ia mayoria le dos datos cllnicos comparatives de Ia especialidaJ tendran que ser generados por medio 92 I Clrn Onh R.s I. 1998;88-91 de disenos no-aleatorizados en el cual se tome precauci6n para mini· mi:ar las varias fuentes desconocidas de prejuicios. Probablemente, no hay ninguna otra manera. fP& ~~10·~~~-~~~~~~~--~~ -~ l.,"CfTbtL"Clt'~=~o:>*<t.t. Jtlt"C.'Jf
